Louisiana State Employees Retirement System Makes New $3.11 Million Investment in Cencora, Inc. $COR

Key Points

• Louisiana State Employees Retirement System bought a new stake in Cencora during the first quarter, purchasing 9,900 shares valued at about $3.11 million.
• Cencora recently reported quarterly earnings below estimates, posting $4.75 EPS versus the expected $4.82 and revenue of $78.36 billion versus the $81.09 billion forecast, though revenue still rose 3.9% year over year.
• The company’s board authorized a $2 billion share buyback and it also paid a quarterly dividend of $0.60 per share, while analysts currently rate the stock a Moderate Buy with a consensus price target of $367.75.

Louisiana State Employees Retirement System purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 9,900 shares of the company's stock, valued at approximately $3,110,000.

A number of other institutional investors also recently modified their holdings of the business. Kemnay Advisory Services Inc. bought a new position in Cencora in the 4th quarter valued at $25,000. Oakworth Capital Inc. bought a new position in shares of Cencora in the fourth quarter worth $26,000. Elyxium Wealth LLC bought a new stake in Cencora during the fourth quarter valued at $27,000. Archer Investment Corp grew its position in Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company's stock worth $28,000 after buying an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC purchased a new position in Cencora during the fourth quarter worth about $29,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Performance

Shares of COR opened at $286.97 on Monday. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The firm has a market capitalization of $55.83 billion, a PE ratio of 22.01, a price-to-earnings-growth ratio of 1.59 and a beta of 0.59. The company has a 50-day simple moving average of $280.84 and a two-hundred day simple moving average of $322.07. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same period in the previous year, the firm earned $4.42 EPS. The company's revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora announced that its board has initiated a stock repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's management believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora's dividend payout ratio (DPR) is presently 18.40%.

Insider Activity at Cencora

In other news, Director Lauren M. Tyler acquired 550 shares of the business's stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of $270.23 per share, with a total value of $148,626.50. Following the completion of the acquisition, the director directly owned 4,359 shares of the company's stock, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.38% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

COR has been the subject of a number of research analyst reports. Wells Fargo & Company dropped their price target on Cencora from $429.00 to $331.00 and set an "overweight" rating for the company in a research report on Monday, May 11th. Barclays lowered their target price on shares of Cencora from $425.00 to $350.00 and set an "overweight" rating on the stock in a research note on Wednesday, June 10th. Robert W. Baird dropped their target price on shares of Cencora from $420.00 to $339.00 and set an "outperform" rating for the company in a research report on Thursday, May 7th. Weiss Ratings lowered shares of Cencora from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, May 22nd. Finally, William Blair started coverage on shares of Cencora in a research report on Tuesday, April 28th. They set a "market perform" rating on the stock. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and a consensus price target of $367.75.

Cencora Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.